Introducing OmniSeq INSIGHTSM
OmniSeq INSIGHTSM is a comprehensive genomic and immune profiling test that is clinically and analytically validated for all solid tumors. OmniSeq INSIGHTSM interrogates the full exonic coding region of 523 genes by next generation sequencing for mutations, select copy number alterations, and fusions/splice variants including genes associated with homologous recombination repair deficiency (HRR/HRD), microsatellite instability (MSI) and tumor mutational burden (TMB), expression of 64 immune genes, and PD-L1 by immunohistochemistry (IHC). The test informs treatment decisions, including targeted and immunotherapy options to which the patient may be more likely to respond, clinical trials, and mechanisms of decreased response and resistance to therapies based on the individual genomic and immune profile for each patient’s tumor.
Expanded Insight = Increased Options
Marker-Driven FDA Approved Therapy Associations
Markers with NCCN Therapeutic Guidance Evidence
Markers with Clinical Trial Associations
Industry-guided content for a comprehensive view of cancer-related fusion genes, detecting common and novel fusions.
Detect Fusions Missed By DNA-seq
Effectively Match Patients to the Right Trial
MOLECULAR + IMMUNE PROFILING = MORE PATIENT OPTIONS
PROFILING THE ACTIONABLE CANCER GENOME
Comprehensive Trial Matching Across the Actionable Cancer Genome for Solid Tumors
Expertly Curated Clinical Trial Matching Assessing Biomarker-Based Eligibility Criteria, Multi-Arm Study Designs and Treatment Context Assertions
PROFILING THE TUMOR MICROENVIRONMENT
Increase Clinical Trial Options by Targeting Biomarkers Involved in the Adaptive Immune System
Understanding the Anti-Cancer Immune Response is Critical to Adapt Therapies to the Cancer Phenotype.
OmniSeq Delivers the Only Test Matching Trials to Tumor-Immune Mechanisms and Low-Expressing Genes Involved in Inflammatory Signaling
Key Clinical Report Features
Solid Tumor Genomic and Immune Profiling
- Detected mutations, rearrangements (fusions/splice variants), copy number changes (gain/loss), TMB, MSI, and PD-L1 (IHC)
- RNA-based detection of fusions and splice variants
- Highly expressed immunotherapy targets for clinical trial identification
- Pertinent negatives for the tested tumor type
- Matched therapies, resistance associations and geographically focused clinical trials
- Potential cancer-associated germline variants flagged
At-a-glance and detailed marker clinical significance and efficacy evidence for matched FDA-approved targeted therapies, immunotherapies, and clinical trials.
Personalized Marker Details
Comprehensive annotation of clinically relevant markers for precision medicine selection and support of molecular tumor boards
Trust a test provider ISO13485:2016 CERTIFIED to design, develop and deliver DNA and RNA testing for the medical management and identification of genomic and immune biomarkers in oncology.